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Introduction 
The use of anti-angiogenic drugs as therapeutic agents for tumor treatment is well known to produce a significant inhibition of tumor angiogenesis 
and tumor growth in vivo. Recently, a new approach for anti-angiogenic agents was proposed consisting of a transient normalisation of tumor 
vasculature during the early stage of an anti-angiogenic treatment (1). This consists of pruning the immature and inefficient blood vessels, leading to 
a transient improvement of tumor perfusion and oxygenation and therefore to a better radiotherapy and chemotherapy efficacy. Our previous study 
concerning the non specific anti-angiogenic agent Thalidomide confirmed this process in FSAII and TLT tumors (2). Similarly, we decided to 
investigate whether another anti-angiogenic agent acting on another target (Flk-1 tyrosine kinase activity) could also normalize the tumor vasculature 
and enhance treatments. We chose to study SU5416, which is known to inhibit endothelial cell proliferation. 
 
Materials and methods 
TLT tumor-bearing mice received daily 100µl i.p. SU5416 injections (25mg/kg) (100µl i.p. DMSO alone for controls). Oxygen pressure (pO2) was 
measured daily by EPR oximetry with a 1.2 GHz spectrometer (Magnettech, Germany). This measurement is based on the variation of the EPR 
linewidth of a paramagnetic oxygen sensor implanted in the tumor. To estimate tumor perfusion and tracer penetration, DCE MRI (4.7 Tesla, Bruker 
Biospec, T1-weighted GRE sequence) was performed using P792 as a contrast agent. A pharmacokinetic analysis using a bicompartmental model 
was performed to extract the plasma volume fraction and the transcapillary flux. The consumption rate of oxygen in tumor cells was measured using 
an X-band EPR spectrometer operating at 9 GHz (Bruker). 
 
Results 
Daily SU5416 treatments increased tumor oxygenation with a maximum level attained two days after the beginning of the treatment (fig.1). 
Surprisingly, this dramatic oxygen increase was not correlated with an increase of tumor perfusion or plasma volume fraction (fig.2). It is therefore 
likely that the increase in tumor oxygenation was due to a decrease in tumor cell oxygen consumption (fig.3).  At the day of the maximum 
oxygenation increase (day 2), the efficacy of radiotherapy (10 Gy of 250 kV RX) was improved (regrowth delay for doubling the tumor size was 
increased by 7.1± 2.8 days for pre-treated group versus control group).  For chemotherapy (cyclophosphamide 50mg/kg), no improvement was 
observed for the pre-treated group. 
 
Discussion 
The improvement of the radiotherapy treatment but not the chemotherapy treatment implied that only the tumor oxygenation status was changed 
during the early phase of SU5416 treatment. In contrast to our previous study with Thalidomide, this increase in pO2 was not likely the result of a 
normalisation process of the tumor vasculature, but instead due to a decrease in tumor cell oxygen consumption rate. This new mechanism for an anti-
angiogenic agent offers a new way to treat tumors by improving the response to radiation. Also, this study demonstrates that combined measurements 
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Fig.1 Effect of SU5416 on TLT tumor 
oxygenation monitored by EPR Oximetry. 
Note the significant increase (p<0.01) in pO2






































































Fig.2 Effect of SU5416 on TLT tumor 
perfusion or plasma volume fraction
monitored by DCE MRI 2 days after the 
beginning of the treatment. No significant 
change (ns) was observed 24 hours after the 
beginning of the treatment 
Fig.3 Effect of SU5416 1µM on TLT tumor
cell oxygen consumption using EPR X-band. 
Note the significant decrease (***;p<0.001) 
of oxygen consumption.  
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